BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Concomitantly activating apoptotic mechanisms and targeting BCR-ABL tyrosine kinase against the CML cells showed promise [60], by ensuring elimination of chronically phased CML stem/ progenitor cells.